ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--$ALT--The Schall Law Firm, a national shareholder rights litigation firm,…
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--$UNCY--The Schall Law Firm, a national shareholder rights litigation firm,…
EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline…
AOUT Investors Have Opportunity to Join American Outdoor Brands, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--$AOUT--The Schall Law Firm, a national shareholder rights litigation firm,…
FCCO Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of First Community Corporation is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating…
MSP Recovery Law Firm Secures Major Legal Win for MSP Recovery as Maryland Supreme Court Upholds Validity of Medicare Recovery Assignments for MSP Recovery and Its Healthcare Clients, Paving the Way for Medicare Recovery Rights Being Pursued Against GEICO
MIAMI, July 12, 2025 (GLOBE NEWSWIRE) -- MSP Recovery Law Firm, counsel…
LECTRA: Monthly declaration of the total number of shares and voting rights composing the company’s capital (at June 30th, 2025)
Monthly declaration of the total number of shares and voting rights composing…
Monthly information on share capital and company voting rights
PARIS, July 04, 2025 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation…
ENNOVI Achieves Prestigious EcoVadis Platinum Sustainability Rating for Unprecedented Fifth Year
Accolade aligns with ENNOVI's mission to positively impact the industries it serves…
Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed…